1. 712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors. (9th November 2020) Authors: Metz, Heather; Brender, Ty; Stevens, Brenda; Winship, Damion; Brevik, Jamie; Comeau, Michael; Childs, Monica; Chang, Jenny; Fan, Li-Qun; Xu, Hengyu; Grey, Jonathan; Adamo, Jeffrey; Setter, Ben; Carrillo, Ray; Smith, Sean; Tan, Phil; DuBose, Robert; Latchman, Yvette; Baum, Peter; Odegard, Valerie Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A754 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors. (9th November 2020) Authors: Metz, Heather; Brender, Ty; Stevens, Brenda; Winship, Damion; Brevik, Jamie; Comeau, Michael; Childs, Monica; Chang, Jenny; Fan, Li-Qun; Xu, Hengyu; Grey, Jonathan; Adamo, Jeffrey; Setter, Ben; Carrillo, Ray; Smith, Sean; Tan, Phil; DuBose, Robert; Latchman, Yvette; Baum, Peter; Odegard, Valerie Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). (4th November 2015) Authors: Drake, Charles G; Quinn, David; Dreicer, Robert; Antonarakis, Emmanuel; Shore, Neal; Corman, John; Concepcion, Raoul; Pieczonka, Christopher; Campogan, Dwayne; Fan, Li-Qun; Chang, Nancy; Sheikh, Nadeem; Petrylak, Daniel Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Induction of antigen spread after sipuleucel-T treatment and its association with improved clinical outcome. (7th November 2013) Authors: GuhaThakurta, Debraj; Fan, Li-Qun; Vu, Tuyen; Sheikh, Nadeem A; Trager, James B Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). Issue 2 (December 2015) Authors: Drake, Charles; Quinn, David; Dreicer, Robert; Antonarakis, Emmanuel; Shore, Neal; Corman, John; Concepcion, Raoul; Pieczonka, Christopher; Campogan, Dwayne; Fan, Li-Qun; Chang, Nancy; Sheikh, Nadeem; Petrylak, Daniel Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗